The clinical outcomes of rituximab biosimilar CT-P10 (Truxima®) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience.
We evaluated real-world effectiveness and safety of CT-P10 (Truxima®) compared with originator rituximab in diffuse large B-cell lymphoma (DLBCL) treatment. Before and after the introduction of CT-P10 to our institute (November 2017), 221 newly-diagnosed DLBCL patients received rituximab with standard cyclophosphamide, vincristine, doxorubicin and prednisone. Patients received originator rituximab throughout (n = 95), switched from originator rituximab to CT-P10 (n = 36), or received CT-P10 throughout (n = 90). There were no significant differences between groups in overall response rate (91.6% vs 94.4% vs 96.7%, respectively; p = 0.403) or complete response rate (84.2% vs 77.8% vs 86.7%, respectively; p = 0.467). Kaplan-Meier survival curves also showed no significant differences in progression-free survival and overall survival between groups (log-rank p = 0.794 and p = 0.955, respectively). Safety profiles were comparable between treatment groups. These data support the ability of CT-P10 to successfully replace originator rituximab in DLBCL treatment and, given the lowered financial barrier, to improve the overall prognosis for DLBCL patients.
['Lee|Kyoungmin|K|0000-0002-6578-7671', 'Ha|Joo Young|JY|', 'Jung|Ah Ra|AR|', 'Lee|Yoon Sei|YS|', 'Lee|Sang-Wook|SW|', 'Ryu|Jin-Sook|JS|', 'Chae|Eun Jin|EJ|', 'Kim|Kyung Won|KW|', 'Huh|Jooryung|J|', 'Park|Chan-Sik|CS|', 'Yoon|Dok Hyun|DH|', 'Suh|Cheolwon|C|']
D058846:Antibodies, Monoclonal, Murine-Derived D000971:Antineoplastic Combined Chemotherapy Protocols D059451:Biosimilar Pharmaceuticals D003520:Cyclophosphamide D004317:Doxorubicin D006801:Humans D016403:Lymphoma, Large B-Cell, Diffuse D011241:Prednisone D000069283:Rituximab D014750:Vincristine
rituximab biosimilar CT-P10 Truxima® Diffuse large B-cell lymphoma real-world evidence